Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
69
JAZZ Quote, Financials, Valuation and Earnings
Last price:
$170.79
Seasonality move
:
4.89%
Day range:
$169.50 - $172.69
52-week range:
$95.49 - $182.99
Dividend yield:
0%
P/E ratio:
15.09x
P/S ratio:
2.51x
P/B ratio:
2.62x
Volume:
313.4K
Avg. volume:
1.4M
1-year change:
38.04%
Market cap:
$10.4B
Revenue:
$4.1B
EPS (TTM):
-$6.07
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
$1.1B | $5.85 | 6.17% | 106.38% | $213.00 |
|
ALKS
Alkermes Plc
|
$356.2M | $0.39 | -11.96% | -54.31% | $43.88 |
|
AMRN
Amarin Corp. Plc
|
$43.1M | -- | -18% | -100% | $12.00 |
|
AVDL
Avadel Pharmaceuticals Plc
|
$73.6M | $0.05 | 59.29% | -76.67% | $20.94 |
|
MDT
Medtronic Plc
|
$8.9B | $1.31 | 7.23% | 32.69% | $110.97 |
|
ZYME
Zymeworks, Inc.
|
$29.9M | -$0.32 | -37.19% | -2.96% | $35.54 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
$170.80 | $213.00 | $10.4B | 15.09x | $0.00 | 0% | 2.51x |
|
ALKS
Alkermes Plc
|
$28.50 | $43.88 | $4.7B | 14.10x | $0.00 | 0% | 3.15x |
|
AMRN
Amarin Corp. Plc
|
$13.75 | $12.00 | $285.9M | -- | $0.00 | 0% | 7.17x |
|
AVDL
Avadel Pharmaceuticals Plc
|
$21.59 | $20.94 | $2.1B | 299.90x | $0.00 | 0% | 8.54x |
|
MDT
Medtronic Plc
|
$97.27 | $110.97 | $124.7B | 26.28x | $0.71 | 2.9% | 3.60x |
|
ZYME
Zymeworks, Inc.
|
$26.86 | $35.54 | $2B | -- | $0.00 | 0% | 15.13x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
57.83% | 0.150 | 67.81% | 1.24x |
|
ALKS
Alkermes Plc
|
3.97% | 0.557 | 1.45% | 3.09x |
|
AMRN
Amarin Corp. Plc
|
1.45% | 2.841 | 1.98% | 2.35x |
|
AVDL
Avadel Pharmaceuticals Plc
|
27.56% | 0.282 | 2.52% | 2.14x |
|
MDT
Medtronic Plc
|
37.43% | 0.567 | 24.98% | 1.50x |
|
ZYME
Zymeworks, Inc.
|
5.58% | 0.545 | 1.46% | 6.69x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals Plc
|
$828.9M | $161.5M | -3.78% | -9.16% | 14.34% | $429.4M |
|
ALKS
Alkermes Plc
|
$341.2M | $89.1M | 20.4% | 22.16% | 22.6% | $84.4M |
|
AMRN
Amarin Corp. Plc
|
$21.2M | -$1.7M | -17.51% | -17.79% | -3.42% | -$12.8M |
|
AVDL
Avadel Pharmaceuticals Plc
|
$80.5M | $1.9M | -0.23% | -0.34% | 2.5% | $23.2M |
|
MDT
Medtronic Plc
|
$5.4B | $1.7B | 6.21% | 9.84% | 19.31% | $457M |
|
ZYME
Zymeworks, Inc.
|
$25M | -$22.1M | -17.82% | -18.82% | -80.07% | -$32.3M |
Jazz Pharmaceuticals Plc vs. Competitors
-
Which has Higher Returns JAZZ or ALKS?
Alkermes Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of 21%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Alkermes Plc's return on equity of 22.16%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B ALKSAlkermes Plc86.56% $0.49 $1.8B -
What do Analysts Say About JAZZ or ALKS?
Jazz Pharmaceuticals Plc has a consensus price target of $213.00, signalling upside risk potential of 24.71%. On the other hand Alkermes Plc has an analysts' consensus of $43.88 which suggests that it could grow by 54%. Given that Alkermes Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Alkermes Plc is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc10 2 0 ALKSAlkermes Plc11 3 0 -
Is JAZZ or ALKS More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.305, which suggesting that the stock is 69.522% less volatile than S&P 500. In comparison Alkermes Plc has a beta of 0.450, suggesting its less volatile than the S&P 500 by 55.029%.
-
Which is a Better Dividend Stock JAZZ or ALKS?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alkermes Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Alkermes Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or ALKS?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Alkermes Plc quarterly revenues of $394.2M. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Alkermes Plc's net income of $82.8M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Alkermes Plc's PE ratio is 14.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.51x versus 3.15x for Alkermes Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.51x 15.09x $1.1B $251.4M ALKSAlkermes Plc3.15x 14.10x $394.2M $82.8M
-
Which has Higher Returns JAZZ or AMRN?
Amarin Corp. Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of -15.58%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Amarin Corp. Plc's return on equity of -17.79%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B AMRNAmarin Corp. Plc42.97% -$0.37 $465.6M -
What do Analysts Say About JAZZ or AMRN?
Jazz Pharmaceuticals Plc has a consensus price target of $213.00, signalling upside risk potential of 24.71%. On the other hand Amarin Corp. Plc has an analysts' consensus of $12.00 which suggests that it could fall by -12.15%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Amarin Corp. Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Amarin Corp. Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc10 2 0 AMRNAmarin Corp. Plc0 1 1 -
Is JAZZ or AMRN More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.305, which suggesting that the stock is 69.522% less volatile than S&P 500. In comparison Amarin Corp. Plc has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.246%.
-
Which is a Better Dividend Stock JAZZ or AMRN?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amarin Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Amarin Corp. Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or AMRN?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Amarin Corp. Plc quarterly revenues of $49.4M. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Amarin Corp. Plc's net income of -$7.7M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Amarin Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.51x versus 7.17x for Amarin Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.51x 15.09x $1.1B $251.4M AMRNAmarin Corp. Plc7.17x -- $49.4M -$7.7M
-
Which has Higher Returns JAZZ or AVDL?
Avadel Pharmaceuticals Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of 0.03%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Avadel Pharmaceuticals Plc's return on equity of -0.34%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B AVDLAvadel Pharmaceuticals Plc90.66% $0.00 $135.6M -
What do Analysts Say About JAZZ or AVDL?
Jazz Pharmaceuticals Plc has a consensus price target of $213.00, signalling upside risk potential of 24.71%. On the other hand Avadel Pharmaceuticals Plc has an analysts' consensus of $20.94 which suggests that it could fall by -2.8%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Avadel Pharmaceuticals Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Avadel Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc10 2 0 AVDLAvadel Pharmaceuticals Plc0 10 0 -
Is JAZZ or AVDL More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.305, which suggesting that the stock is 69.522% less volatile than S&P 500. In comparison Avadel Pharmaceuticals Plc has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.242%.
-
Which is a Better Dividend Stock JAZZ or AVDL?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avadel Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Avadel Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or AVDL?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Avadel Pharmaceuticals Plc quarterly revenues of $77.5M. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Avadel Pharmaceuticals Plc's net income of $20K. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Avadel Pharmaceuticals Plc's PE ratio is 299.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.51x versus 8.54x for Avadel Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.51x 15.09x $1.1B $251.4M AVDLAvadel Pharmaceuticals Plc8.54x 299.90x $77.5M $20K
-
Which has Higher Returns JAZZ or MDT?
Medtronic Plc has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of 15.42%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Medtronic Plc's return on equity of 9.84%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B MDTMedtronic Plc60.45% $1.07 $78B -
What do Analysts Say About JAZZ or MDT?
Jazz Pharmaceuticals Plc has a consensus price target of $213.00, signalling upside risk potential of 24.71%. On the other hand Medtronic Plc has an analysts' consensus of $110.97 which suggests that it could grow by 14.08%. Given that Jazz Pharmaceuticals Plc has higher upside potential than Medtronic Plc, analysts believe Jazz Pharmaceuticals Plc is more attractive than Medtronic Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc10 2 0 MDTMedtronic Plc12 15 0 -
Is JAZZ or MDT More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.305, which suggesting that the stock is 69.522% less volatile than S&P 500. In comparison Medtronic Plc has a beta of 0.710, suggesting its less volatile than the S&P 500 by 28.968%.
-
Which is a Better Dividend Stock JAZZ or MDT?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic Plc offers a yield of 2.9% to investors and pays a quarterly dividend of $0.71 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Medtronic Plc pays out 77.47% of its earnings as a dividend. Medtronic Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios JAZZ or MDT?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are smaller than Medtronic Plc quarterly revenues of $9B. Jazz Pharmaceuticals Plc's net income of $251.4M is lower than Medtronic Plc's net income of $1.4B. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Medtronic Plc's PE ratio is 26.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.51x versus 3.60x for Medtronic Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.51x 15.09x $1.1B $251.4M MDTMedtronic Plc3.60x 26.28x $9B $1.4B
-
Which has Higher Returns JAZZ or ZYME?
Zymeworks, Inc. has a net margin of 22.33% compared to Jazz Pharmaceuticals Plc's net margin of -70.99%. Jazz Pharmaceuticals Plc's return on equity of -9.16% beat Zymeworks, Inc.'s return on equity of -18.82%.
Company Gross Margin Earnings Per Share Invested Capital JAZZJazz Pharmaceuticals Plc73.6% $4.08 $9.4B ZYMEZymeworks, Inc.90.64% -$0.26 $339M -
What do Analysts Say About JAZZ or ZYME?
Jazz Pharmaceuticals Plc has a consensus price target of $213.00, signalling upside risk potential of 24.71%. On the other hand Zymeworks, Inc. has an analysts' consensus of $35.54 which suggests that it could grow by 32.31%. Given that Zymeworks, Inc. has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Zymeworks, Inc. is more attractive than Jazz Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings JAZZJazz Pharmaceuticals Plc10 2 0 ZYMEZymeworks, Inc.12 0 0 -
Is JAZZ or ZYME More Risky?
Jazz Pharmaceuticals Plc has a beta of 0.305, which suggesting that the stock is 69.522% less volatile than S&P 500. In comparison Zymeworks, Inc. has a beta of 1.269, suggesting its more volatile than the S&P 500 by 26.869%.
-
Which is a Better Dividend Stock JAZZ or ZYME?
Jazz Pharmaceuticals Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Jazz Pharmaceuticals Plc pays -- of its earnings as a dividend. Zymeworks, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios JAZZ or ZYME?
Jazz Pharmaceuticals Plc quarterly revenues are $1.1B, which are larger than Zymeworks, Inc. quarterly revenues of $27.6M. Jazz Pharmaceuticals Plc's net income of $251.4M is higher than Zymeworks, Inc.'s net income of -$19.6M. Notably, Jazz Pharmaceuticals Plc's price-to-earnings ratio is 15.09x while Zymeworks, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Jazz Pharmaceuticals Plc is 2.51x versus 15.13x for Zymeworks, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income JAZZJazz Pharmaceuticals Plc2.51x 15.09x $1.1B $251.4M ZYMEZymeworks, Inc.15.13x -- $27.6M -$19.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
